NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

March 28, 2026

Location: 

Sheraton Grand Nashville Downtown

623 Union St, Nashville, TN 37219

7:30am – 3:35pm 

Earn AMA PRA Category 1 Credits,™ and Continuing Nursing Education (ANCC)

Register Now!

Location

Nashville, TN

Course Directors

 

Robert Ramirez, DO, FACP, Associate Professor of Medicine. Division of Hematology and Oncology, Vanderbilt University Medical Center

Deyali Chatterjee, MBBS, Associate Professor of Pathology, Microbiology and Immunology, Vanderbilt University

 

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment, and management of NETs are time-consuming, complex, and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
• Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
• Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
• Recognize the clinical features associated with carcinoid syndrome
• Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
• Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

• • Robert Ramirez, DO, FACP, Associate Professor of Medicine. Division of Hematology and Oncology, Vanderbilt University Medical Center
  • Deyali Chatterjee, MBBS, Associate Professor of Pathology, Microbiology and Immunology, Vanderbilt University

• • Background and Epidemiology of NETs- Are they really rare?
    Simron Singh MD, MPH, Professor, University of Toronto; Chair in Neuroendocrine Cancer Care , Temerty School of Medicine, University of Toronto; Provincial Head, Person Centered Care, Cancer Care Ontario; Medical Oncologist, Sunnybrook Odette Cancer Center/Susan Leslie Clinic for Neuroendocrine Cancers
  • Pathologic Principles - What makes NETs different?
    Deyali Chatterjee, MBBS, Associate Professor of Pathology, Microbiology and Immunology, Vanderbilt University
  • What scans do I order?
    Heather Cole, MD, Assistant Professor, Radiology & Radiological Sciences; Associate Program Director, Nuclear Medicine Residency & Fellowship Programs, Vanderbilt University
  • Moderator: Robert Ramirez, DO, FACP, Associate Professor of Medicine. Division of Hematology and Oncology, Vanderbilt University Medical Center

• • There’s a mass in the pancreas, and it’s a NET! Now what?
    Kamran Idrees, MD, MSCI, MMHC, FACS, Professor of Surgery, Ingram Associate Professor of Cancer Research, Chief, Division of Surgical Oncology & Endocrine Surgery, Vanderbilt University
  • The Bowel Obstruction that won’t go away: The role of surgery, including Cytoreduction in Small Bowel NETs
    J. Philip Boudreaux, MD, FACS, Professor of Surgery, Louisiana State University School of Medicine, New Orleans
  • I have heartburn…or is it? The Gastric Carcinoids: Workup, Diagnosis, and Endoscopic Management
    Phillip S. Ge, MD, Assistant Professor of Medicine, The University of Texas MD Anderson Cancer Center
  • Small Lesion, Big Questions: Management of Rectal NETs
    Christina E. Bailey, MD, MSCI, FACS, Eskind Chair in Surgical Education, Associate Professor of Surgery, Vanderbilt University
  • Moderator: Deyali Chatterjee, MBBS, Associate Professor of Pathology, Microbiology and Immunology, Vanderbilt University

• • The well-differentiated NETs: When surgery is not an option
    Jaydira Del Rivero, MD, Physician Scientist, Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health
  • The poorly-differentiated NECs: When surgery is not an option
    Garima Gupta, MD, Assistant Professor of Medicine, O'Neal Cancer Center, The University of Alabama, Birmingham
  • The Nuclear Option: Peptide Receptor Radionuclide Therapy- what it is and when to use it
    Shana Elman, MD, Program Director and Associate Professor, University of New Mexico
  • Moderator: Robert Ramirez, DO, FACP, Associate Professor of Medicine. Division of Hematology and Oncology, Vanderbilt University Medical Center Ramirez - Vanderbilt

• • Speakers from the AM Sessions
  • Moderator: Robert Ramirez, DO, FACP, Associate Professor of Medicine. Division of Hematology and Oncology, Vanderbilt University Medical Center Ramirez - Vanderbilt

• • Liver-Directed Therapy
    Andrew Marsala, MD, Assistant Professor, Radiology & Radiological Sciences, Vanderbilt University
  • The Torrential Regurgitation: When to suspect and treat Carcinoid Heart Disease
    Brett Heimlich, MD, PhD, Assistant Professor of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center
  • What is coming down the pipeline: Clinical Trials to consider
    Jordan D. Berlin, MD, Associate Director for Clinical Research; Director, Division of Hematology and Oncology, Vanderbilt University
  • Moderator: Deyali Chatterjee, MBBS, Associate Professor of Pathology, Microbiology and Immunology, Vanderbilt University

• • Case Presenters
    Jessica Davis, DO, Hematology/Oncology, Alice and Carl Kirkland Cancer Center
    TBD
  • Panelists
    Jaydira Del Rivero, MD
    J. Philip Boudreaux, MD, FACS
    Andrew Marsala, MD
    Deyali Chatterjee, MD
  • Moderator: Robert Ramirez, DO, FACP, Associate Professor of Medicine. Division of Hematology and Oncology, Vanderbilt University Medical Center

• • Robert Ramirez, DO, FACP, Associate Professor of Medicine. Division of Hematology and Oncology, Vanderbilt University Medical Center
  • Deyali Chatterjee, MBBS, Associate Professor of Pathology, Microbiology and Immunology, Vanderbilt University

*Program is tentative and subject to change* 

Register Now!

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 5.5 hours of continuing nursing education credit.

Registration fee:

NANETS Member

$65 USD - MD, PharmD, Doctoral Level 
$35 USD - Allied Health
$95 USD - Pharmaceutical Employees
Complimentary - Student/Fellow/Resident

Non-Member

$95 USD - MD, PharmD, Doctoral Level 
$50 USD - Allied Health
$125 USD - Pharmaceutical Employees
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before February 27, 2026. On or after February 28, 2026, no refund will be made.

The North American Neuroendocrine Tumor Society reserves the right to modify the activity content, faculty, and activities, and reserves the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.